Potential Future Drug Development Lag in Japan Based on an Analysis of Multiregional Clinical Trials in the US, Europe, and East Asia
Tóm tắt
Although the “drug lag”—namely, the delay in drug approval time in Japan relative to the United States and/or European Union (US/EU)—has been shortened for drugs approved in Japan, there remain many new drugs that have been approved in the US/EU, but not in Japan. To assess the possibility of a future drug lag, this study has examined the current lag in drug development in Japan based on “ClinicalTrials.gov” data from multiregional clinical trials (MRCTs) conducted in the US/EU and East Asia. Among 828 MRCTs registered as of April 5th, 2021, the percentage of MRCTs in which Japan participated (jMRCTs) was 57.1%. jMRCTs were common for some diseases such as “nervous system” and “visual system” disorders, but less common for “neoplasm,” infection,” “mental,” and “circulatory” disorders. Regarding the investigational drugs in non-jMRCTs (i.e., MRCTs without Japanese participation) in the latter four therapeutic areas (i.e., neoplasm, infection, mental and circulatory disorders), approximately 80% (313/399) of drugs were not being developed in Japan. Furthermore, many of these drugs were being developed by the top 50 pharmaceutical companies by sales, and the majority would be recognized as a new active ingredient with a new mode of action in Japan. This study has highlighted the possibility of a future drug lag in Japan, especially in the therapeutic areas of neoplasm, infection, mental, and circulatory disorders. Such a lag may arise not only between Japan and the US/EU, but also between Japan and other countries in the East Asian region.
Tài liệu tham khảo
Bujar M, McAuslane N. New drug approvals in six major authorities 2011–2020: focus on facilitated regulatory pathways and worksharing, R&D Briefing 81. London: Centre for Innovation in Regulatory Science (CIRS); 2021. https://cirsci.org/wp-content/uploads/dlm_uploads/2021/06/CIRS-RD-Briefing-81-6-agencies-v5.pdf. Accessed 9 Jan 2022.
Poirier AF. Closing the drug lag for new drug submission and review in Japan: an industry perspective. Clin Pharmacol Ther. 2015;98(5):486–8.
Ueno T, Asahina Y, Tanaka A, et al. Significant differences in drug-lag in clinical development among various strategies used for regulatory submissions in Japan. Clin Pharmacol Ther. 2014;95(5):533–41.
Pharmaceuticals and Medical Devises Agency. Estimation of drug lag in FY2015–FY2019. Pharmaceuticals and Medical Devises Agency (in Japanese). https://www.pmda.go.jp/files/000238010.pdf. Accessed 9 Jan 2022.
Pharmaceuticals and Medical Devices Agency. Unapproval drug database. Pharmaceuticals and Medical Devices Agency (in Japanese). https://www.pmda.go.jp/review-services/drug-reviews/review-information/p-drugs/0013.html. Accessed 9 Jan 2022.
U.S. National Library of Medicine. ClinicalTrials.gov. U.S. National Library of Medicine. https://clinicaltrials.gov/ct2/home. Accessed 9 Jan 2022.
ICD-11 for mortality and morbidity statistics (version: 05/2021), 2021. https://icd.who.int/browse11/l-m/en. Accessed 9 Jan 2022.
Govindan R, Mandrekar SJ, Gerber DE, et al. ALCHEMIST trials: a golden opportunity to transform outcomes in early-stage non-small cell lung cancer. Clin Cancer Res. 2015;21(24):5439–44.
Kaplan R, Maughan T, Crook A, et al. Evaluating many treatments and biomarkers in oncology: a new design. J Clin Oncol. 2013;31(36):4562–8.
PharmExec.com. 2021 Pharm Exec 50 business and balance, 41: 26–32 2021. https://cdn.sanity.io/files/0vv8moc6/pharmexec/02ef8ca94ed3b155c01330b03c8ccd283a293352.pdf/PharmaceuticalExecutive-June2021-watermark.pdf. Accessed 9 Jan 2022.
JAPIC clinical trials information (in Japanese). https://www.clinicaltrials.jp/cti-user/trial/Search.jsp. Accessed 9 Jan 2022.
Japan Registry of Clinical Trials (in Japanese). https://jrct.niph.go.jp/. Accessed 9 Jan 2022.
Pharmaceuticals and Medical Devices Agency. The list of approved products. https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html. Accessed 9 Jan 2022.
Ichimaru K, Toyoshima S, Uyama Y. Effective global drug development strategy for obtaining regulatory approval in Japan in the context of ethnicity-related drug response factors. Clin Pharmacol Ther. 2010;87(3):362–6.
Nakashima K, Narukawa M, Takeuchi M. Approaches to Japanese dose evaluation in global drug development: factors that generate different dosages between Japan and the United States. Clin Pharmacol Ther. 2011;90(6):836–43.
ICH E17 guideline: general principles for planning and design of multi-regional clinical trials (final version). The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use; 2017. https://database.ich.org/sites/default/files/E17EWG_Step4_2017_1116.pdf. Accessed 9 Jan 2022.
Asano K, Aoi Y, Kamada S, et al. Points to consider for implementation of the ICH E17 Guideline: learning from past multiregional clinical trials in Japan. Clin Pharmacol Ther. 2021;109(6):1555–63.
Kaneko S. A cross-national comparison on the number of basic and clinical research articles published in major journals. OPIR Views Actions. 2015;44:30–1 (in Japanese).
Nishimura T, Shin M, Hanioka K, et al. A cross-national comparison of the number and study characteristics of original articles published in major journals of clinical medicine. J Int Univ Health Welf. 2017;22(1):37–448 (in Japanese).
Alzheimer's Disease Neuroimaging Initiative (ADNI). http://adni.loni.usc.edu/. Accessed 9 Jan 2022.
The Cooperative International Neuromuscular Research Group (CINRG). https://cinrgresearch.org/. Accessed 9 Jan 2022.
Yoshida M. Drug Lag: current situation and characteristics of unapproved new drugs in Japan. OPIR Views Actions. 2021;63:60–70 (in Japanese).
IQVIA. Global trends in R&D—overview through 2020, Institute Report 2021. IQVIA. https://www.iqvia.com/insights/the-iqvia-institute/reports/global-trends-in-r-and-d. Accessed 9 Jan 2022.
Pharmaceuticals and Medical Devices Agency. PMDA updates. Pharmaceuticals and Medical Devices Agency. https://www.pmda.go.jp/english/int-activities/outline/0006.html. Accessed 9 Jan 2022.
Pharmaceuticals and Medical Devices Agency. Profile of services. Pharmaceuticals and Medical Devices Agency. https://www.pmda.go.jp/files/000241469.pdf. Accessed 9 Jan, 2022.
Woodcock J, LaVange LM. Master protocols to study multiple therapies, multiple diseases, or both. N Engl J Med. 2017;377(1):62–70.
Hu C, Dignam JJ. Biomarker-driven oncology clinical trials: key design elements, types, features, and practical considerations. JCO Precis Oncol. 2019;393:1–12.
Avant D, Wharton GT, Murphy D. Characteristics and changes of pediatric therapeutic trials under the Best Pharmaceuticals for Children Act. J Pediatr. 2018;192:8–12.
European Medicines Agency. 10-years Report to the European Commission, General Report on the experience acquired as a result of the application of the Paediatric Regulation, EMA/231225/2015. European Medicines Agency; 2016. https://ec.europa.eu/health/sites/default/files/files/paediatrics/2016_pc_report_2017/ema_10_year_report_for_consultation.pdf. Accessed 9 Jan 2022.
US Food and Drug Administration. Best Pharmaceuticals for Children Act (BPCA) 2002. FDA. https://www.fda.gov/drugs/development-resources/best-pharmaceuticals-children-act-bpca. Accessed 9 Jan 2022.
The European Union. Paediatric Regulation 2007. EU. https://www.ema.europa.eu/en/human-regulatory/overview/paediatric-medicines/paediatric-regulation#:~:text=The%20Paediatric%20Regulation%20is%20comprised%20of%3A%20Regulation%20%28EC%29,relating%20to%20decision%20procedures%20for%20the%20European%20Commission. Accessed 9 Jan 2021.
Ueyama E, Kaneko M, Narukawa M. Analysis of pediatric drug approval lag in Japan. Ther Innov Regul Sci. 2021;55(2):336–45.